In this video, Marlise R. Luskin, MD, MSCE, highlights updates from two groups evaluating blinatumomab and ponatinib for the treatment of acute lymphoblastic leukemia.

Q4 2024 Earnings Call Feb 04, 2025, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants.

In this video, Marlise R. Luskin, MD, MSCE, discusses results from a phase 3 randomized trial that investigated the addition of blinatumomab to standard chemotherapy for pediatric B-cell acute ...

KU School of Medicine-Wichita Department of Pediatrics and Wesley Children’s Hospital say a groundbreaking treatment for ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

From 6 am to 7 am each day (Feb. 5-7th) kids, families, medical experts, and dedicated community members will take over the airwaves for the 22nd annual marathon fundraising event.

The KU School of Medicine-Wichita Department of Pediatrics and Wesley Children’s Hospital recently announced an innovative ...

在癌症治疗领域，最近传来令人振奋的消息：安进公司（Amgen）研发的双特异性抗体疗法Blincyto（blinatumomab）已获得欧盟的批准，成为新确诊的费城染色体阴性CD19阳性B细胞前体急性淋巴细胞白血病（B-ALL）成人患者巩固治疗的一部分。这一里程碑式的批准，主要基于E1910临床3期试验的结果，显示出该疗法在提升患者生存率方面的巨大潜力。

The European Commission (EC) has approved Blincyto (blinatumomab) monotherapy as part of consolidation therapy for the treatment of adults with newly-diagnosed Philadelphia chromosome-negative ...

Amgen’s Blincyto (blinatumomab) has been approved by the European Commission (EC) to treat certain acute lymphoblastic ...

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.